IFNG
Interferon gamma
As of the edition of 20 October 2026, IFNG (interferon gamma, UniProt P01579) has 3 drugs tested at it and 2 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P01579
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 8
- Disease areas
- Blood and lymph; Immune system; Skin and connective tissue; Bones, joints and muscles; Cancer; Digestive system; Heart and blood vessels; Hormones
- Registered trials of its drugs
- 23
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Emapalumab | Marketed | Phase 4 | Ends 2030 |
| AMG-811 | Went quiet | Phase 1 | none listed |
| Fontolizumab | Stopped | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Swedish Orphan Biovitrum | Route B |
| Amgen | Route A |
The other 0 companies at IFNG
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at IFNG, ranked, with the facts behind eachRequest access. Nothing is shown until you do.